Attendee search 

Respinova has developed a new device for the treatment of COPD a group of progressive, debilitating respiratory conditions, including emphysema and chronic bronchitis. COPD is the third leading cause of death. Worldwide there are over 350 million with 50 million in China.
Respinova’s Pulsehaler™ technology is the first and only treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The technology was clinically proven in a clinical study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 15 issued patents and many additional pending patents.
Respinova’s technology pipeline also includes devices for improving delivery of inhaled drugs. This technology was clinically proven to deliver drugs more than 200% better than traditional nebulizers, with significant improvements in lung function. We have begun initial discussions with Pharma companies to partner in the development of Best-in-Class inhaled therapies, including COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.

BioChange is a biotech startup in tissue engineering and regenerative medicine. Our main product is a gelatin based injectable scaffold.

BioChange has developed CellFoam™ , a unique injectable cell adhesive-scaffold that stimulates guided tissue regeneration and supports cell seeding. When CellFoam is injected as stand alone, it completely degrades within the body after about 3 months of a remodeling phase, as new functional tissue is formed, replacing the aged or impaired tissue.

Our first human product is a therapy for skin ageing (BlueStim™ product), it modulates fibroblasts' behavior to regenerate new collagen, regaining skin thickness and quality. In other words, it turns aged skin to young.

The core technology can fit various applications in healthcare such as COPD, macular degeneration, neural repair, periodontal disease, and tissue bioprinting.

Carmel Diagnostics is a medtech company who developed an innovative method for measuring Oxidative Stress (OS) of a biological liquid, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured by TCL (ThermoChemiLuminescence), an advanced yet simple technology. Carmel’s lead product is Embryo Selection in IVF process. Carmel won the prestigious Phase-2 grant from Horizon2020, planning market launch in H1/2021. It has an experienced, motivated team.

Selfit is a digital therapy startup focusing on the aging population and brain and heart conditions.
The company has developed a therapist robot based on AI and neuroscience with focus on physical and cognitive health.

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services

AlephBot is developing a new paradigm in healthcare, the procedure monitor.
The solution helps medical teams maximize treatment efficiency during and after medical procedures (e.g., resuscitation, labor, general anesthesia). It provides the team members with valuable real-time information that is adaptive to their actions and to the procedure’s stage, even if they are under pressure or can’t recall procedure steps by heart. AlephBot also automatically documents the medical procedure, which serves for both medical education and medico-legal purposes.

** AlephBot uniqueness **
We capture the human perspective of a procedure by analyzing the relevant info from the on-going structural medical conversation. We add this layer to the data collected from other sources.
Therefore, we gain higher accuracy of the analyzed medical situation, which enables us to identify the procedure stage and provide meaningful info, in real-time.

** Status **
AlephBot is developing its core technology. The company, pre-seed funded, was selected to the DRIVE accelerator at the Technion (Israel institute of Technology), and received grants from the Israel Innovation Authority.
AlephBot cooperates with big and small hospitals from day one. This serves our intention to increase treatment efficiency both in mega-hospitals in big cities and in smaller ones in the periphery and rural areas.

AlephBot is active in its target markets (Germany, France, Italy and the US) and won several national and international (France, Germany, Denmark) events and competitions. The company is still not active in China - an opportunity!

** Next steps **
We are currently looking for seed investment to finalize our core technology development and bring the product to clinical trial stage in two years. Sales are planned in three years, post regulation clearance.